Key result
CAR-T and BiTE therapies carry substantial cardiovascular toxicities, warranting proactive baseline stratification and monitoring.
Why the study?
Long-term cardiovascular outcomes of CAR-T cell therapy and bispecific T-cell engagers remain poorly characterized, validated surveillance protocols are lacking, and cardiovascular endpoints are rarely included in pivotal trials.
This review highlights the emerging cardio-oncology frontier of T-cell-redirecting therapies, emphasizing the need for proactive baseline risk stratification, serial cardiac biomarker monitoring, and timely management of cardiovascular toxicities.
Answers are grounded in this paper and cite their sources.
Supports vigilant monitoring during T-cell redirecting therapies; leaves open optimal protocols for prospective validation.
Chimeric antigen receptor T-cell therapy and bispecific T-cell engagers have transformed treatment of relapsed and refractory hematologic malignancies, achieving unprecedented response rates. However, their clinical adoption has revealed a complex spectrum of cardiovascular toxicities, differing in frequency and pattern between the two technologies. Manifestations range from common hemodynamic perturbations—hypotension and tachycardia—to severe events, including malignant arrhythmias, left ventricular dysfunction, myocardial infarction, and cardiogenic shock. These complications seem to have different pathophysiological pathways that are yet to be completely understood: on the one hand, they are frequently intertwined with cytokine release syndrome, the hallmark immune complication of T-cell-redirecting therapies, as seen with chimeric antigen receptor T-cell therapy; on the other, a substantial proportion of cardiovascular events—particularly with bispecific T-cell engagers—occur independently of cytokine release syndrome. Proposed cardiotoxic mechanisms include on-target, off-tumor antigen recognition and consequent damage; interleukin-6-driven systemic inflammation; and off-target, off-tumor antigen cross-reactivity. Effective management requires proactive baseline risk stratification, serial cardiac biomarker monitoring, and timely immunosuppressive intervention—primarily tocilizumab—to mitigate cytokine release syndrome-driven injury. Despite rapid clinical expansion, critical gaps remain: long-term cardiovascular outcomes are poorly characterized, validated surveillance protocols are lacking, and cardiovascular endpoints are rarely included in pivotal trials. This narrative review appraises the pathophysiology, clinical spectrum, and management of cardiovascular toxicities associated with these therapies, aiming to define this emerging cardio-oncology frontier, inform multidisciplinary care frameworks and propose a clinical management algorithm.
No takes yet. Share an insight, caveat, or question.
Tedeschi et al. (2026) conducted a review in Hematologic malignancies. CAR-T cell therapy and bispecific T-cell engagers (BiTEs) was evaluated. CAR-T cell therapy and bispecific T-cell engagers are associated with significant cardiovascular toxicities, including hypotension, arrhythmias, and left ventricular dysfunction, necessitating proactive baseline risk stratification and monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: